Laryngomedin Antisept (Octenidine Dihydrochloride)

Octenidine Dihydrochloride acts by binding to phospholipid components of bacterial cell membranes, disrupting their integrity. This rapid loss of membrane function leads to cell death, providing broad‑spectrum activity against both Gram‑positive and Gram‑negative microorganisms without targeting specific metabolic pathways.

The appropriate dose of Laryngomedin Antisept is determined by the prescribing healthcare professional based on the indication, patient age, and clinical condition. No fixed regimen is provided here; clinicians should follow local guidelines and product labeling.

Safety data for octenidine dihydrochloride in pregnancy and lactation are limited. Consequently, the product should be used only if the potential benefit justifies any possible risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both octenidine and chlorhexidine are broad‑spectrum antiseptics, but octenidine typically shows lower cytotoxicity and less staining of oral tissues. Chlorhexidine may have a longer substantivity, while octenidine offers rapid bactericidal action and a lower risk of developing resistance in some settings.

Store the solution at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from moisture, direct sunlight and extreme temperatures. Keep out of reach of children and avoid contamination of the applicator tip during use.

Laryngomedin Antisept is applied directly to the oral mucosa or throat using the supplied applicator or a clean swab. The recommended contact time is typically 30 seconds to one minute, after which the patient may expectorate or swallow according to the prescriber’s instructions.

The most serious adverse events include severe allergic reactions such as anaphylaxis, extensive chemical burns of the oral mucosa, and rare systemic toxicity. Users should discontinue the product immediately and seek medical attention if they experience signs of a severe reaction.

Individuals with a known hypersensitivity to octenidine or other bisbiguanides should avoid the product. It is also contraindicated on large ulcerated lesions, in patients with severe mucosal damage, and should be used with caution in children, pregnant or lactating women when safety data are insufficient.